International Journal of Biological Macromolecules · 2025 · 17 citations · 102 references
PharmacyNeurosciencePharmacologyDrug DeliveryNanoparticle Drug DeliveryNeuropharmacologyBlood-brain Barrier DeliveryBrain Targeted DeliveryNanocarriers For TherapeuticsNanomedicineNanoparticle FormulationsOral NanocarriersAntidepressant EfficacyBlood-brain Barrier PermeabilityChitosan-based NanomaterialsLipid Nanoparticle DeliveryLipid-based Brain Delivery SystemsLipid-based Drug CarriersOral Nanoparticle BioavailabilityTargeted Delivery Across The Blood-brain Barrier
Phytochemicals have emerged as promising candidates for next-generation therapeutics targeting neurological disorders. Among them, quercetin (QU) has shown potential in alleviating depression and preventing cognitive decline. However, its clinical utility is limited by poor oral bioavailability and restricted permeability across the blood-brain barrier (BBB). To address these challenges, QU was encapsulated in chitosan-coated nanostructured lipid carriers (QU-CS-NLCs), forming a novel nano-system to enhance brain-directed delivery and therapeutic efficacy. QU-CS-NLCs exhibited nanometric particle size, sustained-release behavior, and structural integrity, as confirmed by Fourier transform infrared (FT-IR) spectroscopy, differential scanning calorimetry (DSC), and X-ray diffraction (XRD). Superior therapeutic efficacy of QU-CS-NLCs over pure QU and the standard antidepressant fluoxetine was observed in a lipopolysaccharide (LPS) -induced mouse model of depression and anxiety. Behavioral assays revealed improved mood and anxiety parameters, including increased sucrose preference, prolonged struggle time, and reduced immobility. Moreover, QU-CS-NLCs led to a 65.4 % reduction in C-reactive protein (CRP), a 145.2 % increase in brain serotonin, and a 331.8 % increase in brain-derived neurotrophic factor (BDNF), alongside restoration of TrkB receptor expression. Histopathological analysis further confirmed significant neuroprotective effects. These findings underscore the enhanced antidepressant potential of QU-CS-NLCs, offering a promising alternative to conventional QU or Fluoxetine therapies.
102
Depression: a new animal model sensitive to antidepressant treatments
Roger D. Porsolt, Manuel Pichon, M Jalfre · Nature · 1977 · 4.4K citations
Medicine, Neuroscience, Psychiatry +12
Twelve-Month Use of Mental Health Services in the United States
Philip S. Wang, Michael Lane, Mark Olfson et al. · Archives of General Psychiatry · 2005 · 2.7K citations
Cross-national epidemiology of DSM-IV major depressive episode
Evelyn J. Bromet, Laura Helena Andrade, Irving Hwang et al. · BMC Medicine · 2011 · 2.2K citations · Full text
Medicine, Demography, Psychiatry +17